Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugs for Neglected Diseases initiative

www.dndi.org

Latest From Drugs for Neglected Diseases initiative

Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 


Pipeline Watch Approvals

Pipeline Watch: Kisqali, SI-6603, Cosentyx Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access

US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.

Infectious Diseases Rare Diseases

DNDi Adds Affordable Ravidasvir Combo To Asian HCV Trials

DNDi is progressing its five-year initiative to improve access to affordable combination therapies for hepatitis C through new agreements for ravidasvir, which will be tested in trials in Malaysia and Thailand.

BioPharmaceutical Asia Pacific
See All
UsernamePublicRestriction

Register